Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeu… Read more
Market Cap & Net Worth: Panacea Biotec Limited (PANACEABIO)
Panacea Biotec Limited (NSE:PANACEABIO) has a market capitalization of $224.34 Million (₹19.43 Billion) as of March 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #20635 globally and #1053 in its home market, demonstrating a -5.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Panacea Biotec Limited's stock price ₹317.20 by its total outstanding shares 61250746 (61.25 Million).
Panacea Biotec Limited Market Cap History: 2015 to 2026
Panacea Biotec Limited's market capitalization history from 2015 to 2026. Data shows growth from $94.91 Million to $224.34 Million (8.30% CAGR).
Panacea Biotec Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Panacea Biotec Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Panacea Biotec Limited's market cap is 0.05 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $83.10 Million | $6.53 Billion | -$182.90 Million | 0.01x | N/A |
| 2017 | $171.86 Million | $5.25 Billion | -$562.00 Million | 0.03x | N/A |
| 2018 | $113.27 Million | $5.86 Billion | -$739.78 Million | 0.02x | N/A |
| 2019 | $92.86 Million | $4.52 Billion | $377.27 Million | 0.02x | 0.25x |
| 2020 | $169.42 Million | $5.37 Billion | -$1.94 Billion | 0.03x | N/A |
| 2021 | $140.67 Million | $6.18 Billion | -$1.48 Billion | 0.02x | N/A |
| 2022 | $100.47 Million | $6.59 Billion | $10.78 Billion | 0.02x | 0.01x |
| 2023 | $118.75 Million | $4.57 Billion | -$332.37 Million | 0.03x | N/A |
| 2024 | $296.06 Million | $5.52 Billion | -$11.73 Million | 0.05x | N/A |
| 2025 | $266.14 Million | $5.59 Billion | -$83.70 Million | 0.05x | N/A |
Competitor Companies of PANACEABIO by Market Capitalization
Companies near Panacea Biotec Limited in the global market cap rankings as of March 19, 2026.
Key companies related to Panacea Biotec Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Panacea Biotec Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Panacea Biotec Limited's market cap moved from $94.91 Million to $ 224.34 Million, with a yearly change of 8.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹224.34 Million | -15.71% |
| 2025 | ₹266.14 Million | -10.11% |
| 2024 | ₹296.06 Million | +149.32% |
| 2023 | ₹118.75 Million | +18.20% |
| 2022 | ₹100.47 Million | -28.58% |
| 2021 | ₹140.67 Million | -16.97% |
| 2020 | ₹169.42 Million | +82.44% |
| 2019 | ₹92.86 Million | -18.01% |
| 2018 | ₹113.27 Million | -34.09% |
| 2017 | ₹171.86 Million | +106.81% |
| 2016 | ₹83.10 Million | -12.44% |
| 2015 | ₹94.91 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Panacea Biotec Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $224.34 Million USD |
| MoneyControl | $224.34 Million USD |
| MarketWatch | $224.34 Million USD |
| marketcap.company | $224.34 Million USD |
| Reuters | $224.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.